Search Results - "Basho, Reva K"

Comparative Effectiveness of an mTOR‐Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple‐Negative Breast Cancer by Basho, Reva K., Yam, Clinton, Gilcrease, Michael, Murthy, Rashmi K., Helgason, Thorunn, Karp, Daniel D., Meric‐Bernstam, Funda, Hess, Kenneth R., Valero, Vicente, Albarracin, Constance, Litton, Jennifer K., Chavez‐MacGregor, Mariana, Hong, David, Kurzrock, Razelle, Hortobagyi, Gabriel N., Janku, Filip, Moulder, Stacy L.

“…Background Triple‐negative breast cancer (TNBC) is a heterogeneous disease with subtypes having different “targetable” molecular aberrations. Metaplastic…”
Get full text

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer by Basho, Reva K., McArthur, Heather L.

“…The development of human epidermal growth factor 2 (HER2)-directed therapy has resulted in significant improvement in outcomes for patients with early-stage…”
Get full text

Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer by Ziyeh, Sharvina, Wong, Lauren, Basho, Reva K.

“…Purpose of Review To provide an overview of the current management of hormone receptor-positive (HR +) advanced breast cancer as well as highlight ongoing…”
Get full text

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP by Litton, Jennifer K, Regan, Meredith M, Pusztai, Lajos, Rugo, Hope S, Tolaney, Sara M, Garrett-Mayer, Elizabeth, Amiri-Kordestani, Laleh, Basho, Reva K, Best, Ana F, Boileau, Jean-Francois, Denkert, Carsten, Foster, Jared C, Harbeck, Nadia, Jacene, Heather A, King, Tari A, Mason, Ginny, O'Sullivan, Ciara C, Prowell, Tatiana M, Richardson, Andrea L, Sepulveda, Karla A, Smith, Mary Lou, Tjoe, Judy A, Turashvili, Gulisa, Woodward, Wendy A, Butler, Lynn Pearson, Schwartz, Elena I, Korde, Larissa A

“…The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of…”
Get full text

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab by Basho, Reva K, Gilcrease, Michael, Murthy, Rashmi K, Helgason, Thorunn, Karp, Daniel D, Meric-Bernstam, Funda, Hess, Kenneth R, Herbrich, Shelley M, Valero, Vicente, Albarracin, Constance, Litton, Jennifer K, Chavez-MacGregor, Mariana, Ibrahim, Nuhad K, Murray, 3rd, James L, Koenig, Kimberly B, Hong, David, Subbiah, Vivek, Kurzrock, Razelle, Janku, Filip, Moulder, Stacy L

“…Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide…”
Get more information

Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes by Basho, Reva K, Zhao, Li, White, Jason B, Huo, Lei, Bassett, Roland L, Mittendorf, Elizabeth A, Thompson, Alastair, Litton, Jennifer K, Ueno, Naoto, Arun, Banu, Lim, Bora, Valero, Vicente, Tripathy, Debu, Zhang, Jianhua, Adrada, Beatriz E, Santiago, Lumarie, Ravenberg, Elizabeth, Seth, Sahil, Yam, Clinton, Moulder, Stacy L, Damodaran, Senthil

“…The PI3K pathway is frequently altered in triple-negative breast cancer (TNBC). Limited cell line and human data suggest that TNBC tumors characterized as…”
Get more information

Clinical outcomes based on multigene profiling in metastatic breast cancer patients by Basho, Reva K, de Melo Gagliato, Debora, Ueno, Naoto T, Wathoo, Chetna, Chen, Huiqin, Shariati, Maryam, Wei, Caimiao, Alvarez, Ricardo H, Moulder, Stacy L, Sahin, Aysegul A, Roy-Chowdhuri, Sinchita, Chavez-MacGregor, Mariana, Litton, Jennifer K, Valero, Vincent, Luthra, Raja, Zeng, Jia, Shaw, Kenna R, Mendelsohn, John, Mills, Gordon B, Tripathy, Debu, Meric-Bernstam, Funda

“…Identifying the clinical impact of recurrent mutations can help define their role in cancer. Here, we identify frequent hotspot mutations in metastatic breast…”
Get full text

Sentinel node biopsy and regional recurrence following neoadjuvant chemotherapy in patients with isolated tumor cells: A rare event by Moody, Alison, Jutla, Jaswinder, Chung, Alice P., Basho, Reva K, Giuliano, Armando E.

“…e12581 Background: Lack of consensus exists regarding the optimal surgical axillary management of breast cancer patients treated with neoadjuvant therapy…”
Get full text

Individualized treatment estimates to inform on personalized cancer care decisions for treatment selection and treatment management by Walsh, David, Srivatsa, Sumana, George, Renee, Ellis, Ben, Aljehani, Mayada, Gross, Mitchell E., Basho, Reva K., Matasci, Naim, Swisher, Christine

“…e13571 Background: Clinical trials report average effects of treatments at a population level. However, clinicians must balance treatment benefits against…”
Get full text

Interplay between B cell and GABA metabolism (GABAm) and association with immune evasion in breast carcinoma (BC) by Chow, Frances Elaine, Kang, Irene, Yin, Jun, Farrell, Alex, Martirosian, Vahan, Jayachandran, Priya, Roussos Torres, Evanthia T., Lu, Janice M., Lenz, Heinz-Josef, Ma, Cynthia X., McArthur, Heather L., Basho, Reva K, Spetzler, David, Neman, Josh

“…1097 Background: GABAergic signaling has been reported to play a pivotal role in breast cancer (BC) tumorigenesis and metastasis, however, its role in immune…”
Get full text

A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer by McArthur, Heather L., Comen, Elizabeth Anne, Bryce, Yolanda, Solomon, Stephen Barnett, Leal, Jorge Henrique S., Abaya, Christina DiLauro, Martinez, Cristal, Basho, Reva K, McAndrew, Philomena, Larkin, Brigid, Page, David B., Mellinger, Staci L., Fredrich, Nicole, Moxon, Nicole, Reddy, Sangeetha M., Carter, Meredith, Patil, Sujata, Dogan, Basak, Gatti-Mays, Margaret Elena, Norton, Larry

“…TPS635 Background: Local tumor destruction with cryoablation (cryo) induces inflammation and releases antigens that can activate tumor-specific immune…”
Get full text

Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial by McArthur, Heather L., Leal, Jorge, Shiao, Stephen Lawrence, Carter, Meredith, Basho, Reva K, Phillips, Michelle, Chan, David, Hool, Hugo, Park, Dorothy J., El-Masry, Mary, McAndrew, Philomena, Sikaria, Swati, Spring, Laura, Bardia, Aditya, Tighiouart, Mourad, Dadmanesh, Farnaz, Giuliano, Armando E., Sanchez, Katherine, Page, David B.

“…TPS634 Background: Immune checkpoint inhibition (ICI) is synergistic with HER2-directed therapy in pre-clinical models. Clinically, pembrolizumab (K)-mediated…”
Get full text

A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer by McArthur, Heather L., Comen, Elizabeth Anne, Bryce, Yolanda, Solomon, Stephen Barnett, Leal, Jorge Henrique S., Abaya, Christina DiLauro, Martinez, Cristal, Basho, Reva K, Park, Dorothy J., McAndrew, Philomena, Larkin, Brigid, Mills, William, Page, David B., Mellinger, Staci L., Fredrich, Nicole, Moxon, Nicole, Reddy, Sangeetha M., Carter, Meredith, Patil, Sujata, Norton, Larry

“…TPS617 Background: Local tumor destruction with cryoablation (cryo) induces inflammation and releases antigens that can activate tumor-specific immune…”
Get full text

Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress) by Meisel, Jane Lowe, Pluard, Timothy J., Vinayak, Shaveta, Stringer-Reasor, Erica Michelle, Brown-Glaberman, Ursa, Dillon, Patrick Michael, Basho, Reva K, Varadarajan, Ramya, O'Shaughnessy, Joyce, Han, Hyo S., Sinha, Rajni, Fox, Jenny R., Villanueva, Rafael, Chen, Lin Chi, Wu, Sheng, Li, Hong, Tran, Sinhan, Manso, Luis

“…TPS1127 Background: Patients with metastatic triple-negative breast cancer (mTNBC) have a poor prognosis. Treatment combinations of anti-programmed death…”
Get full text

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design by Cooper, Benjamin T., Chmura, Steven J., Luke, Jason J., Shiao, Stephen Lawrence, Basho, Reva K, Iams, Wade Thomas, Page, David B., Li, Cong, Gregory, Richard C., Shaw, Michael, Horn, Kristin, Gibbs, John, Appleman, Vicky A., Berger, Allison J., Abu-Yousif, Adnan, Lineberry, Neil, Stumpo, Kate, Elfiky, Aymen, Gerber, Naamit Kurshan

“…TPS2698 Background: The cyclic GMP-AMP Synthase (cGAS)–STimulator of INterferon Genes (STING) pathway is an important modulator of the innate immune system via…”
Get full text

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial by McArthur, Heather L., Leal, Jorge Henrique S., Page, David B., Abaya, Christina DiLauro, Basho, Reva K, Phillips, Michelle, Chan, David, Hool, Hugo, Park, Dorothy J., El-Masry, Mary, McAndrew, Philomena, Sikaria, Swati, Spring, Laura, Bardia, Aditya, Tighiouart, Mourad, Dadmanesh, Farnaz, Giuliano, Armando E., Shiao, Stephen Lawrence

“…TPS624 Background: Immune checkpoint inhibition (ICI) is synergistic with HER2-directed therapy in pre-clinical models. Clinically, pembrolizumab (K)-mediated…”
Get full text

Analysis of immune checkpoint blockade biomarkers in elderly patients using large-scale cancer genomics data by Erbe, Rossin, Wang, Zheyu, Wu, Sharon, Xiu, Joanne, Zaidi, Neeha, Lippman, Marc E., Isaacs, Claudine, Basho, Reva K, Lenz, Heinz-Josef, Astsaturov, Igor A., Marshall, John, Baylin, Stephen, Jaffee, Elizabeth M., Roussos Torres, Evanthia T., Weeraratna, Ashani, Easwaran, Hariharan, Fertig, Elana J.

“…Abstract only 2543 Background: Immune checkpoint blockade (ICB) immunotherapy in some cases elicits striking patient responses, but its efficacy appears to be…”
Get full text

Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes by Basho, Reva K, Trevarton, Alex, Hess, Kenneth R., Fu, Chunxiao, Lau, Rosanna, Lin, Chih-Hsu, Lichtarge, Olivier, Yang, Wei Tse, Symmans, William Fraser, Moulder, Stacy L.

“…Abstract only…”
Get full text

Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes by Basho, Reva K, Yam, Clinton, White, Jason B, Zhao, Li, Huo, Lei, Mittendorf, Elizabeth A., Thompson, Alastair Mark, Litton, Jennifer Keating, Arun, Banu, Lim, Bora, Valero, Vicente, Tripathy, Debu, Zhang, Jianhua, Adrada, Beatriz E, Santiago, Lumarie, Ravenberg, Elizabeth, Moulder, Stacy L., Damodaran, Senthil

“…Abstract only 561 Background: Limited cell line and human data suggest that TNBCs characterized as mesenchymal and luminal androgen receptor (LAR) commonly…”
Get full text

Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC) by Page, David B., Chun, Brie, Pucilowska, Joanna, Kim, Isaac, Sanchez, Katherine, Redmond, William L, Sun, Zhaoyu, Wu, Yaping, Feryn, Alicia, Martel, Maritza, Abaya, Christina DiLauro, Wadell, Dottie, Mellinger, Staci L., Moxon, Nicole, Urba, Walter John, McAndrew, Philomena, El-Masry, Maryliza, Basho, Reva K., Conlin, Alison Katherine, McArthur, Heather L.

“…Abstract only 1015 Background: Atezolizumab (anti-PD-L1) plus nab-paclitaxel was shown to improve outcomes in mTBNC in a phase III clinical trial. Subjects…”
Get full text